Psychiatry · Medical Literature
A pilot study of pharmacogenomic testing as a tool to enhance depression care in Veterans.
Abstract
Modest outcomes from pharmacogenomic (PGx) testing in depression may be influenced by low rates of actionable gene-drug interactions. This 12-week pilot pragmatic randomized clinical trial evaluated the effectiveness of selectively targeting PGx testing to depressed Veterans receiving psychiatric polypharmacy with an antidepressant on the Sanford Pharmacogenomics Panel. 60 Veterans were randomized to having their PGx test results available immediately or delayed until the end of the 12-week trial. Patient Health Questionnaire-9 (PHQ-9) scores were assessed monthly by blinded raters, with medication changes assessed via the electronic medical record. 30% of subjects had an actionable gene-drug interaction, compared to 20% in prior PGx research in Veterans. There were no significant differences in PHQ-9 scores, proportion of patients with medication changes, or time to first medication change. This study showed that targeted PGx testing can increase rates of actionable genotypes in patients with depression.
Clinical relevance
Does selectively targeting pharmacogenomic (PGx) testing to depressed Veterans already receiving psychiatric polypharmacy with an antidepressant on the Sanford Pharmacogenomics Panel increase the rate of actionable gene-drug interactions and improve depression outcomes compared to delayed result disclosure over 12 weeks? __SNAPSHOT__ {"studyDesign":"Pilot pragmatic randomized controlled trial (delayed-disclosure control design)","setting":"Veterans Affairs health care system (specific institution[s] not reported in abstract); United States","sampleSize":"n=60 (immediate results: n=30, delayed results: n=30)","population":"Depressed Veterans receiving psychiatric polypharmacy that included an antidepressant on the Sanford Pharmacogenomics Panel; additional inclusion criteria not reported in abstract","intervention":"PGx test results made immediately available to the treating clinician at enrollment (immediate-disclosure arm)","comparator":"PGx test results withheld from the treating clinician until end of the 12-week trial (delayed-disclosure control arm)","primaryOutcome":"Not explicitly designated in the abstract; outcomes assessed included PHQ-9 score trajectory, proportion of patients with medication changes, and time to first medication change","followUp":"12 weeks","fundingSource":"Not reported"}
Key findings
The primary mechanistic finding was that targeted selection of patients already receiving psychiatric polypharmacy with an antidepressant on the Sanford panel yielded an actionable gene-drug interaction rate of 30%, compared to approximately 20% reported in prior, broader PGx research in Veterans — a 10 percentage point absolute difference (calculated), though statistical significance of this enrichment comparison was not reported. On clinical outcomes, there were no statistically significant between-group differences in PHQ-9 scores at any assessment point, in the proportion of patients who underwent a medication change, or in time to first medication change. No specific effect sizes, confidence intervals, p-values, or NNT/NNH data were reported for any endpoint. Adverse events were not reported in the abstract.
Practice implications
This study established only that a targeted enrichment strategy — restricting PGx testing to Veterans already on antidepressants within a specific panel under psychiatric polypharmacy — can modestly increase the proportion of patients with actionable genotypes compared to historical controls in the same population. It did not establish any clinical benefit: PHQ-9 scores, medication change rates, and time-to-first medication change were not significantly different between arms. The study cannot determine whether the observed 30% actionable-genotype rate translates into improved treatment decisions or outcomes in practice. The population was exclusively Veterans (predominantly male, with high rates of PTSD and comorbid psychiatric conditions), limiting generalizability to broader depressed populations. As only an abstract was available for this review, the completeness of outcome reporting, blinding fidelity, handling of missing data, and any subgroup analyses cannot be assessed. Given the pilot nature and the absence of clinical outcome benefit, findings should be considered hypothesis-generating only; no practice change is warranted on the basis of this study alone. __LIMITATIONS__ 1. Very small sample size (n=60) with inadequate statistical power to detect meaningful clinical differences; explicitly described as a pilot study. 2. Short 12-week follow-up may be insufficient to detect delayed clinical benefit from PGx-guided prescribing changes. 3. The comparison of actionable-genotype rate (30% vs. 20%) is drawn against historical controls rather than a concurrent randomized comparator, introducing selection and temporal confounding. 4. No formal primary endpoint was pre-specified in the abstract, raising concerns about outcome multiplicity and interpretive flexibility. 5. Statistical significance and effect sizes were not reported for any outcome, limiting the ability to assess the precision of null findings. 6. Blinding of raters for PHQ-9 was reported, but clinician and patient blinding status is not fully described. 7. The Veterans-only population limits generalizability; this demographic has high rates of PTSD, combat-related comorbidities, and male predominance not representative of broader depressed populations. 8. Funding source is not reported, precluding assessment of potential conflicts of interest. 9. Pragmatic design with medication changes assessed via electronic medical record may not capture all clinically relevant prescribing decisions or adherence. 10. Only the abstract was available for review; full methodological details (randomization sequence, allocation concealment, attrition, fidelity checks) could not be assessed. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small 12-week pilot RCT found that targeting PGx testing to Veterans on antidepressant-containing psychiatric polypharmacy using the Sanford panel increased the actionable gene-drug interaction rate to 30% versus a historical 20% benchmark, but produced no significant differences in depressive symptom scores, medication change rates, or time to first medication change. The study is hypothesis-generating and underpowered to draw clinical conclusions. No change in practice is supported; confirmation in an adequately powered trial is required before targeted PGx enrichment strategies can be recommended.